Market Overview

LifeTech Capital Downgrades Marina Biotech To Neutral, $0.30 PT


LifeTech Capital downgraded its Marina Biotech (NASDAQ: MRNA) rating from Strong Speculative Buy to Neutral and lowered its Marina Biotech price target from $2.50 to $0.30 in a research report published today. LifeTech Capital

In the report, LifeTech Capital states, "Although Marina's announced financing is expected to yield much needed cash to the company (closing on or about May 20th), the terms result in significant dilution that adversely impacts projected earnings per share in our financial model beyond our projected dilution for future capital requirements."

Shares of Marina Biotech were trading at $0.24 at the time of posting, down 3.08% from Tuesday's market close.


Related Articles (MODERNA)

View Comments and Join the Discussion!

Posted-In: LifeTech CapitalAnalyst Color Downgrades Price Target Analyst Ratings

Latest Ratings

VOYAPiper SandlerMaintains58.0
PRUPiper SandlerMaintains64.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at